Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5Breast 4Thoracic 3Classical hematology 3Plasma cell 2Other solid neoplasm 1Myeloid 1Gynecologic 1

Conditions

Solid Tumors 1

Interventions

Cisplatin 42Pemetrexed 31Carboplatin 28Nivolumab 21pembrolizumab 19Gemcitabine 19atezolizumab 13Etoposide 13Injections 12Ipilimumab 11Cyclophosphamide 11Radiotherapy 10Oxaliplatin 10Filgrastim 10Docetaxel 10Bevacizumab 10tislelizumab 9Vincristine 9Specimen Handling 9durvalumab 8Paclitaxel 8Capecitabine 8tremelimumab 7toripalimab 7lenvatinib 7Everolimus 7spartalizumab 6olaparib 6niraparib 6Vinorelbine 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × pegylated granulocyte colony-stimulating factor × Other solid neoplasm × Clear all
NCT06926751 2026-05-07

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
132 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡